WO2012158983A3 - Entreposage amélioré de plaquettes à l'aide d'un inhibiteur de sialidase - Google Patents

Entreposage amélioré de plaquettes à l'aide d'un inhibiteur de sialidase Download PDF

Info

Publication number
WO2012158983A3
WO2012158983A3 PCT/US2012/038462 US2012038462W WO2012158983A3 WO 2012158983 A3 WO2012158983 A3 WO 2012158983A3 US 2012038462 W US2012038462 W US 2012038462W WO 2012158983 A3 WO2012158983 A3 WO 2012158983A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
present
sialidase
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/038462
Other languages
English (en)
Other versions
WO2012158983A2 (fr
Inventor
Qiyong Peter Liu
Karin Hoffmeister
Robert Sackstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
ZymeQuest Inc
Original Assignee
Brigham and Womens Hospital Inc
ZymeQuest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, ZymeQuest Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA2835434A priority Critical patent/CA2835434A1/fr
Priority to AU2012255137A priority patent/AU2012255137A1/en
Priority to JP2014511561A priority patent/JP2014515352A/ja
Priority to CN201280023800.4A priority patent/CN103702556A/zh
Priority to EP12726520.5A priority patent/EP2709446A2/fr
Priority claimed from US13/474,679 external-priority patent/US20120294842A1/en
Priority claimed from US13/474,627 external-priority patent/US20120321722A1/en
Publication of WO2012158983A2 publication Critical patent/WO2012158983A2/fr
Anticipated expiration legal-status Critical
Publication of WO2012158983A3 publication Critical patent/WO2012158983A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/124—Disinfecting agents, e.g. antimicrobials
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne une solution additive plaquettaire (SAP) présentant une certaine quantité d'un ou de plusieurs inhibiteurs de sialidase et éventuellement d'un ou de plusieurs agents de modification de glycane ; et un ou plusieurs composants de PAS qui incluent un sel, une source de citrate, une source de carbone et une quelconque combinaison de ceux-ci. La présente invention concerne également des procédés, des compositions et des kits destiné(e)s à augmenter le temps de circulation in vivo de plaquettes isolées par l'entreposage des plaquettes en présence d'un ou de plusieurs inhibiteurs de sialidase. De plus, la présente invention concerne des procédés et des compositions destiné(e)s à réduire l'activité de la sialidase et à inhiber la prolifération bactérienne d'une ou de plusieurs bactéries dans une préparation de produits plaquettaires à partir d'un ou de plusieurs donneurs.
PCT/US2012/038462 2011-05-17 2012-05-17 Entreposage amélioré de plaquettes à l'aide d'un inhibiteur de sialidase Ceased WO2012158983A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2835434A CA2835434A1 (fr) 2011-05-17 2012-05-17 Entreposage ameliore de plaquettes a l'aide d'un inhibiteur de sialidase
AU2012255137A AU2012255137A1 (en) 2011-05-17 2012-05-17 Improved platelet storage using a sialidase inhibitor
JP2014511561A JP2014515352A (ja) 2011-05-17 2012-05-17 シアリダーゼ阻害剤を用いた血小板の保存の改善法
CN201280023800.4A CN103702556A (zh) 2011-05-17 2012-05-17 使用唾液酸酶抑制剂改进的血小板保存
EP12726520.5A EP2709446A2 (fr) 2011-05-17 2012-05-17 Stockage de plaquettes sanguines en utilisant un sialidase inhibiteur

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201161487077P 2011-05-17 2011-05-17
US61/487,077 2011-05-17
US201161503984P 2011-07-01 2011-07-01
US61/503,984 2011-07-01
US201261613837P 2012-03-21 2012-03-21
US201261613876P 2012-03-21 2012-03-21
US61/613,837 2012-03-21
US61/613,876 2012-03-21
US13/474,679 US20120294842A1 (en) 2011-05-17 2012-05-17 Platelet Additive Solution Having a Sialidase Inhibitor
US13/474,679 2012-05-17
US13/474,473 2012-05-17
US13/474,627 US20120321722A1 (en) 2011-05-17 2012-05-17 Platelet Storage and Reduced Bacterial Proliferation In Platelet Products Using A Sialidase Inhibitor
US13/474,473 US20120321601A1 (en) 2011-05-17 2012-05-17 Increased In Vivo Circulation Time of Platelets After Storage With A Sialidase Inhibitor
US13/474,627 2012-05-17

Publications (2)

Publication Number Publication Date
WO2012158983A2 WO2012158983A2 (fr) 2012-11-22
WO2012158983A3 true WO2012158983A3 (fr) 2014-01-03

Family

ID=49716421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/038462 Ceased WO2012158983A2 (fr) 2011-05-17 2012-05-17 Entreposage amélioré de plaquettes à l'aide d'un inhibiteur de sialidase

Country Status (6)

Country Link
EP (1) EP2709446A2 (fr)
JP (1) JP2014515352A (fr)
CN (1) CN103702556A (fr)
AU (1) AU2012255137A1 (fr)
CA (1) CA2835434A1 (fr)
WO (1) WO2012158983A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
EP2903430A1 (fr) * 2012-10-05 2015-08-12 Velico Medical, Inc. Solution additive plaquettaire comprenant un inhibiteur de bêta-galactosidase
CA2896053A1 (fr) * 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Procedes de production de plaquettes a partir de cellules souches pluripotentes, et compositions associees
WO2014120886A1 (fr) * 2013-01-30 2014-08-07 Velico Medical, Inc. Solution additive plaquettaire ayant un peptide formant un hydrogel à auto-assemblage
WO2016057041A1 (fr) * 2014-10-09 2016-04-14 Biovec Transfusion, Llc Compositions et procédés de conservation de fonction de plaquettes
US10897891B2 (en) 2015-04-10 2021-01-26 Board Of Regents, The University Of Texas System Compositions and methods for prolonged cell storage
EP3317402B1 (fr) 2015-06-30 2024-02-14 Universidade Nova de Lisboa Population de cellules viables, procédé de production et utilisations de celle-ci
JP7287634B2 (ja) * 2015-10-14 2023-06-06 株式会社メガカリオン 精製血小板の製造方法
CN111235132A (zh) * 2019-12-23 2020-06-05 浙江工业大学 一种β-半乳糖苷酶、基因、工程菌及其应用
CN117717059A (zh) * 2022-09-09 2024-03-19 河络新图生物科技(上海)有限公司 一种血小板保存液及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
WO2006044790A2 (fr) * 2004-10-15 2006-04-27 Zymequest, Inc. Compositions et procedes d'allongement de la survie de plaquettes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412835A (en) 1982-07-06 1983-11-01 E. I. Du Pont De Nemours & Company Sterile docking process, apparatus and system
US5256559A (en) 1988-03-04 1993-10-26 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5152905A (en) 1989-09-12 1992-10-06 Pall Corporation Method for processing blood for human transfusion
US5236716A (en) 1990-02-12 1993-08-17 Miles Inc. Platelets concentrate with low white blood cells content
US5569579A (en) 1991-04-01 1996-10-29 Thomas Jefferson University Synthetic-based platelet storage media
US5376524A (en) 1991-04-01 1994-12-27 Thomas Jefferson University Platelet storage medium containing acetate and phosphate
US5269946A (en) 1991-05-22 1993-12-14 Baxter Healthcare Corporation Systems and methods for removing undesired matter from blood cells
US5234808A (en) 1991-10-30 1993-08-10 Thomas Jefferson University Acetate addition to platelets stored in plasma
US5344752A (en) 1991-10-30 1994-09-06 Thomas Jefferson University Plasma-based platelet concentrate preparations
US5474891A (en) 1991-10-30 1995-12-12 Thomas Jefferson University Plasma-based platelet concentrate preparations with additive
WO1996014740A1 (fr) 1992-03-02 1996-05-23 Cerus Corporation Produits synthetiques pour preparations sanguines
US5529821A (en) 1992-06-29 1996-06-25 Terumo Kabushiki Kaisha Container for storing blood or blood component
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5582821A (en) 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
US6221669B1 (en) 1994-10-19 2001-04-24 Lifecell Corporation Prolonged preservation of blood platelets
US5919614A (en) 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
US5622867A (en) 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
JPH09509681A (ja) 1994-12-16 1997-09-30 バクスター、インターナショナル、インコーポレイテッド 供血者血液特性の制御
JP2930908B2 (ja) 1995-07-19 1999-08-09 川澄化学工業株式会社 血小板保存液
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
WO1999026926A1 (fr) 1997-11-26 1999-06-03 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines et alcoxyguanidines et leur utilisation en tant qu'inhibiteurs de protease
KR20010034328A (ko) 1998-01-23 2001-04-25 와이너 길버트 피. 생체액 처리 시스템
US6344486B1 (en) 1998-04-03 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
AU750561B2 (en) 1998-04-24 2002-07-25 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
NZ508669A (en) 1998-06-11 2003-06-30 Dimensional Pharm Inc Pyrazinone protease inhibitors
MXPA01011956A (es) 1999-05-27 2002-06-21 Dimensional Pharm Inc Oxazaheterociclos como inhibidores de proteasas.
EP1194428B1 (fr) 1999-07-09 2003-09-17 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de protease heteroaryle et agents d'imagerie diagnostique
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
US6476016B2 (en) 2000-07-17 2002-11-05 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
MXPA03000963A (es) 2000-08-04 2004-04-05 Dimensional Pharm Inc Inhibidores de oxiguanidina ciclica proteasa.
UA75093C2 (en) 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
AU2002213202A1 (en) 2000-10-13 2002-04-22 Pike Laboratories, Inc. Organ and tissue preservation cold storage solution
US6605302B2 (en) 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
AU2004235777B9 (en) 2003-05-01 2009-02-05 Thermics Corporation Method and system for warming a fluid
US7527934B2 (en) 2004-07-26 2009-05-05 The Regents Of The University Of California Labeled substrate conjugates for identifying enzyme inhibitors
EP1796457B1 (fr) 2004-09-07 2011-11-23 Velico Medical, Inc. Appareil permettant de prolonger la survie des plaquettes
WO2008054475A2 (fr) 2006-03-13 2008-05-08 The Trustees Of Columbia University In The City Of New York Inhibiteurs de neuraminidase, et leurs utilisations
US7998740B2 (en) 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
CN101181302A (zh) * 2007-11-29 2008-05-21 中国人民解放军军事医学科学院野战输血研究所 一种保养液以及一种血小板保存液

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459030A (en) * 1992-03-02 1995-10-17 Steritech, Inc. Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
WO2006044790A2 (fr) * 2004-10-15 2006-04-27 Zymequest, Inc. Compositions et procedes d'allongement de la survie de plaquettes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GERARD JANSEN ET AL: "Surface Sialic Acid Prevents Loss of GPIb{alpha} during Platelet Storage and Rescues In Vivo Survival of Murine Platelets", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11, 1 January 2007 (2007-01-01), XP009173318, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2012158983A2 (fr) 2012-11-22
AU2012255137A1 (en) 2013-12-12
CA2835434A1 (fr) 2012-11-22
CN103702556A (zh) 2014-04-02
EP2709446A2 (fr) 2014-03-26
JP2014515352A (ja) 2014-06-30

Similar Documents

Publication Publication Date Title
WO2012158983A3 (fr) Entreposage amélioré de plaquettes à l'aide d'un inhibiteur de sialidase
NZ607600A (en) Compositions for the treatment of diseases
EP3354640A3 (fr) Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3409666A3 (fr) Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
WO2013052803A3 (fr) Procédés et compositions comportant un promoteur de nitrite réductase pour le traitement de troubles médicaux et la conservation de produits sanguins
MX373236B (es) Compuestos condensados de [1,4]diazepina como inhibidores de producción de la autotaxina (atx) y ácido lisofosfatidico (lpa).
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
MX2014015197A (es) Tratamiento y prevencion de la enfermedad cardiovascular y trombosis.
MX352760B (es) Metodos para tratar infecciones intrapulmonares.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PH12017501019B1 (en) Isoxazole hydromaxamic acid compounds as lpxc inhibitors
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
PH12014501032A1 (en) 2-thiopyrimidinones
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
GEP20156346B (en) Imidazole derivatives as pde10a enzyme inhibitors
IN2015DN01151A (fr)
SG10201900541QA (en) Derivatives of xanthone compounds
IN2014MN01465A (fr)
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2012007662A (es) Compuestos anti-heparina.
EA201490638A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ РАКА C ПРИМЕНЕНИЕМ ИНГИБИТОРА PI3Kβ И ИНГИБИТОРА СИГНАЛЬНОГО ПУТИ MAPK, ВКЛЮЧАЯ MEK И RAF ИНГИБИТОРЫ
EA201490674A1 (ru) Консервирующая композиция для напитков и/или соусов
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12726520

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2835434

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014511561

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012726520

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012726520

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012255137

Country of ref document: AU

Date of ref document: 20120517

Kind code of ref document: A